The effect of Qi-Shao-Tong-Mai-An-Shen herbal paste on coronary heart disease patients with depression and/or anxiety: Study protocol for a randomized controlled trial

Abstract

Coronary heart disease (CHD) poses a significant threat to human life and well-being. The presence of psycho-cardiology diseases not only exacerbates the progression of CHD but also imposes a substantial financial burden. Consequently, there is a pressing need to prioritize the prevention and management of psycho-cardiology conditions. Given the complex adverse effects associated with antidepressants, it is imperative to investigate alternative, safer, and more efficacious early interventions for psycho-cardiology diseases. The trial will randomly divide 99 patients who meet the inclusion criteria into two groups in a ratio of 1:2. Both groups will be administered standard western medicine treatment for CHD. The Qi-Shao-Tong-Mai-An-Shen (QSTMAS) group will be treated with an additional 30 mL QSTMAS herbal paste orally twice daily for up to 12 weeks. The primary endpoints are the changes of Generalized Anxiety Disorder-7 and Patient Health Questionnaire-9 scores after the intervention for 12 weeks. The secondary endpoints include the scores of Traditional Chinese medicine syndromes, 6-min walking test, Insomnia severity index sleep scale, laboratory tests, and other examinations of both groups after the intervention for 12 weeks. The QSTMAS herbal paste exhibits potential and promise as a treatment modality for mild-to-moderate psychological disorders within the department of cardiology. The implementation of a rigorous trial design will facilitate an objective and scientific assessment of the clinical effectiveness and safety of combining QSTMAS herbal paste with standard western medicine for CHD patients with depression and/or anxiety. Trial Registration: China Clinical Trial Registry, ChiCTR2200065179. Registered 31 October 2022.

Keywords

anxiety / coronary heart disease / depression / Qi-Shao-Tong-Mai-An-Shen herbal paste / traditional Chinese medicine

References

[1] Doenst T , Haverich A , Serruys P , et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2019; 73 (8): 964- 976.

[2] Jia S , Liu Y , Yuan J . Evidence in guidelines for treatment of coronary artery disease. Adv Exp Med Biol. 2020; 1177: 37- 73.

[3] Malakar AK , Choudhury D , Halder B , Paul P , Uddin A , Chakraborty S . A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019; 234 (10): 16812- 16823.

[4] Ferrari AJ , Charlson FJ , Norman RE , et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013; 10 (11): e1001547.

[5] Yusuf S , Reddy S , Ounpuu S , Anand S . Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104 (22): 2746- 2753.

[6] Mozaffarian D , Benjamin EJ , Go AS , et al. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation. 2016; 133 (4): e38- e360.

[7] McGuire AW , Eastwood JA , Hays RD , Macabasco-O'Connell A , Doering LV . Depressed or not depressed: untangling symptoms of depression in patients hospitalized with coronary heart disease. Am J Crit Care. 2014; 23 (2): 106- 116.

[8] Frasure-Smith N , Lespérance F , Talajic M . Depression following myocardial infarction. Impact on 6-month survival. JAMA. 1993; 270 (15): 1819- 1825.

[9] Lespérance F , Frasure-Smith N , Talajic M , Bourassa MG . Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002; 105 (9): 1049- 1053.

[10] Székely A , Balog P , Benkö E , et al. Anxiety predicts mortality and morbidity after coronary artery and valve surgery-a 4-year follow-up study. Psychosom Med. 2007; 69 (7): 625- 631.

[11] Frasure-Smith N , Lespérance F . Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatr. 2008; 65 (1): 62- 71.

[12] Tully PJ , Baker RA , Knight JL . Anxiety and depression as risk factors for mortality after coronary artery bypass surgery. J Psychosom Res. 2008; 64 (3): 285- 290.

[13] Moser DK , McKinley S , Riegel B , et al. Relationship of persistent symptoms of anxiety to morbidity and mortality outcomes in patients with coronary heart disease. Psychosom Med. 2011; 73 (9): 803- 809.

[14] Watkins LL , Koch GG , Sherwood A , et al. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. J Am Heart Assoc. 2013; 2 (2): e000068.

[15] James SL , Abate D , Abate KH , et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392 (10159): 1789- 1858.

[16] Blumenthal JA , Smith PJ , Jiang W , et al. Effect of exercise, escitalopram, or placebo on anxiety in patients with coronary heart disease: the understanding the benefits of exercise and escitalopram in anxious patients with coronary heart disease (UNWIND) randomized clinical trial. JAMA Psychiatr. 2021; 78 (11): 1270- 1278.

[17] Findling RL , Robb A , Bose A . Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. J Child Adolesc Psychopharmacol. 2013; 23 (7): 468- 480.

[18] Solmi M , Fornaro M , Ostinelli EG , et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatr. 2020; 19 (2): 214- 232.

[19] Barbui C , Ostuzzi G . Medicine-based evidence: the case of antidepressants in patients with coronary artery disease. Epidemiol Psychiatr Sci. 2019; 28 (1): 18- 20.

[20] Ma H , Wang Y , Xue Y , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomed Pharmacother. 2019; 112: 108639.

[21] Sun J , Zhou M , Lv G , et al. Xinkeshu improves endothelial function and augments reendothelialization capacity in coronary artery disease with anxiety/depression. Oxid Med Cell Longev. 2021; 2021: 5561272- 5561314.

[22] Chen M , Liu M , Guo X , et al. Effects of Xinkeshu tablets on coronary heart disease patients combined with anxiety and depression symptoms after percutaneous coronary intervention: a meta-analysis. Phytomedicine. 2022; 104: 154243.

[23] Deng F , Li X , Tang C , et al. Mechanisms of Xiong-Pi-Fang in treating coronary heart disease associated with depression: a systematic pharmacology strategy and in vivo pharmacological validation. J Ethnopharmacol. 2022; 298: 115631.

[24] Zhu C . Clinical Experience and Network Pharmacology Research on Treatment of Chest Impediment by Warm Period Medical Prescription and Treatment of Coronary Heart Disease by Professor Huang Li. Beijing University of Chinese Medicine. 2021 (in Chinese).

[25] Gong L , Chang H , Zhang J , Guo G , Shi J , Xu H . Astragaloside Ⅳ protects rat cardiomyocytes from hypoxia-induced injury by down-regulation of miR-23a and miR-92a. Cell Physiol Biochem. 2018; 49 (6): 2240- 2253.

[26] Lu M , Tang F , Zhang J , et al. Astragaloside Ⅳ attenuates injury caused by myocardial ischemia/reperfusion in rats via regulation of toll-like receptor 4/nuclear factor-κB signaling pathway. Phytother Res. 2015; 29 (4): 599- 606.

[27] Wei D , Xu H , Gai X , Jiang Y . Astragaloside Ⅳ alleviates myocardial ischemia-reperfusion injury in rats through regulating PI3K/AKT/GSK-3β signaling pathways. Acta Cir Bras. 2019; 34 (7): e201900708.

[28] Si J , Wang N , Wang H , et al. HIF-1α signaling activation by post-ischemia treatment with astragaloside Ⅳ attenuates myocardial ischemia-reperfusion injury. PLoS One. 2014; 9 (9): e107832.

[29] Zhang S , Tang F , Yang Y , et al. Astragaloside Ⅳ protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis. PLoS One. 2015; 10 (3): e0118759.

[30] Tu L , Pan CS , Wei XH , et al. Astragaloside Ⅳ protects heart from ischemia and reperfusion injury via energy regulation mechanisms. Microcirculation. 2013; 20 (8): 736- 747.

[31] Lu M , Leng B , He X , Zhang Z , Wang H , Tang F . Calcium sensing receptor-related pathway contributes to cardiac injury and the mechanism of astragaloside Ⅳ on cardioprotection. Front Pharmacol. 2018; 9: 1163.

[32] Zhu Y , Huang DM , JuY H , et al. Mechanism of astragaloside Ⅳ in treatment of depression based on network pharmacology and molecular docking. Drugs Clinic. 2022; 37 (11): 2465- 2474 (in Chinese).

[33] Chan AW , Tetzlaff JM , Gøtzsche PC , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346. e7586.

[34] Cheng CW , Wu TX , Shang HC , et al. CONSORT extension for Chinese herbal medicine formulas 2017: Recommendations, explanation, and elaboration. Ann Intern Med. 2017; 167 (2): 112- 121.

[35] Section of Interventional Cardiology of Chinese Society of Cardiology, Section of Atherosclerosis and Coronary Artery Disease of Chinese Society of Cardiology and Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians . Guideline on the diagnosis and treatment of stable coronary artery disease. Chin J Cardio. 2018 (9): 680- 694 (in Chinese).

[36] Du JH , Shi ZX . Consensus on the diagnosis and treatment of blood stasis syndrome with integrated traditional Chinese and Western medicine. Chin J Integr Med. 2011; 31 (06): 839- 844 (in Chinese).

[37] Spitzer RL , Kroenke K , Williams JB , Löwe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166 (10): 1092- 1097.

[38] Kroenke K , Spitzer RL , Williams JB . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16 (9): 606- 613.

[39] Knuuti J , Wijns W , Saraste A , et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41 (3): 407- 477.

[40] Hu D . How did I realize and propose "double heart medicine. Chin J Cardiol. 2021; 49 (06): 543- 544 (in Chinese).

[41] Hagström E , Norlund F , Stebbins A , et al. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med. 2018; 283 (1): 83- 92.

[42] Harshfield EL , Pennells L , Schwartz JE , et al. Association between depressive symptoms and incident cardiovascular diseases. JAMA. 2020; 324 (23): 2396- 2405.

[43] Dupre ME , Nelson A , Lynch SM , et al. Socioeconomic, psychosocial and behavioral characteristics of patients hospitalized with cardiovascular disease. Am J Med Sci. 2017; 354 (6): 565- 572.

[44] Tillmann T , Pikhart H , Peasey A , et al. Psychosocial and socioeconomic determinants of cardiovascular mortality in Eastern Europe: a multicentre prospective cohort study. PLoS Med. 2017; 14 (12): e1002459.

[45] Grace SL , Medina-Inojosa JR , Thomas RJ , et al. Antidepressant use by class: association with major adverse cardiac events in patients with coronary artery disease. Psychother Psychosom. 2018; 87 (2): 85- 94.

[46] China expert consensus on psychological prescription for patients with cardiovascular disease . Zhonghua Nei Ke Za Zhi, 2020, 59 (10): 764- 771.

[47] World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects . JAMA, 2013, 310 (20): 2191- 2194.

[48] Idänpään-Heikkilä JE . WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. Ann Med. 1994; 26 (2): 89- 94.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Advanced Chinese Medicine published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.